Ignite Creation Date:
2024-05-06 @ 1:06 PM
Last Modification Date:
2024-10-26 @ 1:09 PM
Study NCT ID:
NCT03936218
Status:
RECRUITING
Last Update Posted:
2024-05-17
First Post:
2019-04-29
Brief Title:
Goserelin 108mg Injection in Treatment of Advanced Prostate Cancer
Sponsor:
Eurofarma Laboratorios SA
Organization:
Eurofarma Laboratorios SA
Study Overview
Official Title:
A Two Arm Multi Centric Randomised Open Label Parallel Study to Compare Pharmacodynamics of Subcutaneous Goserelin 108mg Injection Sponsor With ZOLADEX 108mg Injection AstraZeneca in Patients With Advanced Prostate Cancer
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A two arm multi centric randomized open label parallel two doses pharmacodynamics study in patients with advanced prostate cancer
Detailed Description:
A phase III two arm multi centric randomized open label parallel two doses pharmacodynamics study in patients with advanced prostate cancer Each patient will have 25 visits total Total duration of the study will be 183 days including up to 14 days of screening
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None